Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer

Anti-Cancer Drugs

Volumn 14, Issue 2, 2003, Pages 103-110

  De Bree, Eelco ^a   Rosing, Hilde ^b   Beijnen, Jos H ^b   Romanos, John ^a   Michalakis, John ^a   Georgoulias, Vasilis ^a   Tsiftsis, Dimitris D ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Docetaxel; Hyperthermia; i.p. chemotherapy; Ovarian cancer; Pharmacokinetics

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; MELPHALAN; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURGERY; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HEMATOMA; HUMAN; HYPERTHERMIC THERAPY; LEUKOPENIA; NAUSEA; OVARY CANCER; PATIENT SELECTION; PERITONEAL CAVITY; PERITONEAL FLUID; PEROPERATIVE CARE; PRIORITY JOURNAL; PSYCHOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARCINOMA; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INJECTIONS, INTRAPERITONEAL; INTRAOPERATIVE CARE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; TAXOIDS; TISSUE DISTRIBUTION;

EID: 0037331578     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200302000-00003     Document Type: Article

References (55)

1. Thigpen JT. Chemotherapy for advanced ovarian cancer: overview of randomized trials. Semin Oncol 2000; 27(suppl 7):11-16.
2. Kaye SB. Future directions for the management of ovarian cancer. Eur J Cancer 2001; 37:S19-S23.
3. McGuire III WP. High-dose chemotherapeutic approaches to ovarian cancer management. Semin Oncol 2000; 27(suppl 7):41-46.
4. Ozols RF, Gore M, Trope C, Grenman S. Intraperitoneal treatment and dose-intense therapy in ovarian cancer. Ann Oncol 1999; 10(suppl 1):S59-64.
5. Hofstra LS, de Vries EGE, Mulder NH, Willemse PHB. Intraperiteneal chemotherapy in ovarian cancer. Cancer Treat Rev 2000; 26:133-143.
6. Markman M. Intraperiteneal therapy of ovarian cancer. Semin Oncol 1998; 25:356-260.
7. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphomide for stage III ovarian cancer. N Engl J Med 1996; 335:150-155.
8. Markman M, Bundy B, Alberts DS, Fowler JM, Clark-Pearson DJ, Carson LF, et al. Phase III study of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:1001-1007.
9. Markman M, Reichman B, Hakes T, Jones W, Lewis Jr JL, Rubin S, et al. Responses to second-line cisplatin based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991; 9:1801-1805.
10. Cortes JE, Padzur R. Docetaxel. J Clin Oncol 1995; 13:2643-2655.
11. Kaye SB, Piccad M, Aapro, Francis P, Kavanagh J. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer. An updated overview. Eur J Cancer 1997; 33:2167-2170.
12. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol™) and docetaxel (Taxotere™): not simply two of a kind. Ann Oncol 1994; 5:495-505.
13. Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes E, Steger M, Nelson-Taylor T, et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 2000; 18:2733-2739.
14. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998; 16:3362-3368.
15. Reed E, Bitton R, Sarosy G, Kohn E. Paclitaxel dose intensity. J Infus Chemother 1996; 6:59-63.
16. Markman M, Rowinsky E, Hakes T, Reichman B, Walter J, Lewis JL, et al. Phase I trial of intraperitoneal Taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992; 10:1485-14891.
17. Markman M. Intraperitoneal Taxol. Cancer Treat Res 1996; 81:1-5.
18. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16:2610-2624.
19. Padovani A, de Bennedetto A, Domini P, Madelli O, Cortesi E. Intraperitoneal paclitaxel plus dose escalation of carboplatin in untreated stage III epithelial ovarian cancer. Proc Am Soc Clin Oncol 1998; 17:1433.
20. Marchettini P, Stuart OA, Mohamed F, Yoo D, Sugarbaker PH. Docetaxel: pharmacokinetics and tissue distribution after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol 2002; 49:499-503.
21. Zaffaroni N, Fiorentini G, De Giorgi U. Hyperthermia and hypoxia: new developments in anticancer chemotherapy. Eur J Surg Oncol 2001; 27:340-342.
22. Witkamp AJ, de Bree E, van Goethem R, Zoetmulder FA. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27:365-374.
23. de Bree E, van Ruth S, Baas P, Rutgers EJ, van Zandwijk N, Witkamp AJ, et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002; 121:480-487.
24. de Bree E, Witkamp AJ, Zoetmulder FA. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. Br J Surg 2000; 88:152-156.
25. Ceelen WP, Hesse U, de Hemptinne B, Pattyn P. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. Br J Surg 2000; 87:1006-1015.
26. Pilati P, Rossi CR, Mocellin S, Foletto M, Scagnet B, Pasetto L, et al. Multimodality treatment of peritoneal carcinomatosis and sarcomatosis. Eur Surg Oncol 2001; 27:125-134.
27. Cavaliere F, Perri P, Di Filippo F, Giannarelli D, Botri C, Cosimelli M, et al. Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol 2000; 74:41-44.
28. Fujimura T, Yonemura Y, Fujita H, Michiwa Y, Kawamura T, Nojima N, et al. Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various abdominal malignancies. Int Surg 1999; 84:60-66.
29. Nicoletto MO, Padrini R, Galeotti F, Ferrazzi E, Cartei G, Riddi F, et al. Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. Cancer Chemother Pharmacol 2000; 45:457-462.
30. Orlando M, Huertas E, Salum G, Loza J, Coló F, Vilanova M, et al. Intraperitoneal hyperthermic chemotherapy as consolidation treatment for ovarian cancer in pathological complete remission. Proc Am Soc Clin Oncol 1998; 17:1432.
31. Steller MA, Egorin MJ, Trimble EL, Bartlett DL, Zuhowski EG, Alexander HR, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother Pharmacol 1999; 43:106-114.
32. Panteix G, Beaujard A, Garbit F, Chaduiron-Faye C, Guillaumont M, Gilly F, et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res 2002; 22:1329-1336.
33. van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998; 34:148-154.
34. van der Vange N, van Goethem AR, Zoetmulder FAN, Kaag MM, Van de Vaart PJM, ten Bokkel Huinink WW, et al. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 2000; 26:663-668.
35. de Bree E, Christodoulakis M, Tsiftsis D. Malignant peritoneal mesothelioma treated by continuous hyperthermic peritoneal perfusion chemotherapy. Ann Oncol 2000; 11:753-756.
36. de Bree E, Witkamp AJ, Zoetmulder FA. Peroperative hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer. Eur J Surg Oncol 2000; 26:630-631.
37. de Bree E, Witkamp AJ, Zoetmulder FA. Intraperitoneal chemotherapy in colorectal cancer. J Surg Oncol 2002; 79:46-61.
38. Tsiftsis D, de Bree E, Romanos J, Petrou A, Sanidas E, Askoxylakis J, et al. Peritoneal expansion by artificially produced ascites during perfusion chemotherapy. Arch Surg 1999; 134:545-549.
39. Witkamp AJ, de Bree E, Kaag MM, Witkamp AJ, de Bree E, Kaag MM, et al. Extensive cytoreductive surgery followed by intraoperative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis from colorectal origin. Eur J Cancer 2001; 37:979-984.
40. Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive surgical cytoreduction and intra-operative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001; 88:458-463.
41. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Branch for Breast Cancer. J Clin Oncol 1997; 15:3149-3155.
42. Rosing H, Lustig V, Koopman FJ, ten Bokkel Huinink WW, Beijnen JH. Bioanalysis of docetaxel and hydroxylated metabolites in human plasma by high-performance chromatography and automated solid-phase extraction. J Chromatogr B 1997; 696:89-98.
43. Markman M. Intraperitoneal chemotherapy. Semin Oncol 1991; 18:248-254.
44. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 1997; 89:480-487.
45. Dumontet C, Bodin F, Michal Y. Potential interactions between antitubulin agents and temperature: implications for modulation of multidrug resistance. Clin Cancer Res 1998; 4:1563-1566.
46. Rietbroek RC, Katschinski DM, Reijers MH, Robins HI, Geerdink A, Tutsch K, et al. Lack of thermal enhancement for taxanes in vitro. Int J Hyperthermia 1997; 13:525-533.
47. Leal BZ, Meltz ML, Mohan N, Kuhn J, Prihoda TJ, Herman TS. Interaction of hyperthermia with Taxol in human MCF-7 breast adenocarcinoma cells. Int J Hyperthermia 1999; 15:225-236.
48. Ohtman T, Goto S, Lee JB, Taimura A, Matsumoto T, Kosaka M. Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel. Pharmacology 2001; 62:208-212.
49. Cividalli A, Cruciani G, Livdi E, Pasqualetti P, Tirindelli Danesi D. Hyperthermia enhances the response of paclitaxel and radiation in a mouse adenocarcinoma. Int J Radiat Oncol Biol Phys 1999; 44:407-412.
50. Cividalli A, Livdi E, Ceciarelli F, Piscitelli M, Pasqualetti P, Cruciani G, et al. Hyperthermia and paclitaxel-epirubicin chemotherapy: enhanced cytotoxic effect in a murine mammary adenocarcinoma. Int J Hyperthermia 2000; 16:61-71.
51. Cho H-K, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, et al. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol 1999; 39:394-401.
52. Rosing H, Lustig V, van Warmerdam LJ, Huizing MT, ten Bokkel Huinink WW, Schellens JHM, et al. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol 2000; 45:213-218.
53. Ascherman JA, Knowles SL, Attkiss K. Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations. Ann Plast Surg 2000; 45:438-441.
54. Raley J, Geisler JP, Buekers TE, Sorosky JI. Docetaxel extravasation causing significant delayed tissue injury. Gynecol Oncol 2000; 78:259-260.
55. Kotsakis A, Sarra E, Peraki M, Koukourakis M, Apostolaki S, Souglakos J, et al. Docetaxel-induced lymphopenia in patients with solid tumors: a prospective phenotypic analysis. Cancer 2000; 89:1380-1386.